| Literature DB >> 22670838 |
Attapon Cheepsattayakorn1, Ruangrong Cheepsattayakorn.
Abstract
A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22670838 DOI: 10.2174/157489112801619683
Source DB: PubMed Journal: Recent Pat Antiinfect Drug Discov ISSN: 1574-891X